Michael Hedvat

This inventor holds 19 USPTO granted patents and 19 published patent applications and 2 EPO patents, primarily in Immunotherapy Antibodies. Top assignees: Xencor, Inc., Genentech, Inc.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Hedvat. Retrieved from https://idiyas.com/inventor/michael-hedvat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 19)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 15)

Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 45(Granted Patents)

Location History:

Encino, CA (US) (2020 - 2024)
Pasadena, CA (US) (2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2020-2026

Loading Chart...

Areas of Expertise:

Anti-CD28 Compositions

Bispecific Antibodies

PD-1 Targeting

IL-10 Fc-Fusion Proteins

Prostate Specific Membrane Antigen

Heterodimeric Antibodies

Checkpoint Inhibitors

Combination Therapies

Costimulatory Receptors

IL-15 Fusion Proteins

Mesothelin Binding Domains

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703748 - Anti-CD28 compositions (2026-08-11),

2. 12698341 - ANTIGEN BINDING DOMAINS THAT BIND TO MESOTHELIN (MSLN) (2026-08-04),

3. 12404329 - Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 (2025-09-02),

4. 12378326 - Anti-CD28 x anti-PSMA antibodies (2025-08-05),

5. 12365743 - Anti-CD28 x anti-PSMA antibodies (2025-07-22),

6. 12152076 - Bispecific and monospecific antibodies using novel anti-PD-1 sequences (2024-11-26),

7. 12006345 - Untargeted and targeted IL-10 Fc-fusion proteins (2024-06-11),

8. 11932675 - PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties (2024-03-19),

9. 11919958 - Anti-CD28 compositions (2024-03-05),

10. 11919956 - Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 (2024-03-05),

11. 11851466 - Targeted IL-12 heterodimeric Fc-fusion proteins (2023-12-26),

12. 11591401 - Anti-CD28 compositions (2023-02-28),

13. 11492407 - Bispecific checkpoint inhibitor antibodies (2022-11-08),

14. 11377477 - PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof (2022-07-05),

15. 11312770 - Bispecific and monospecific antibodies using novel anti-PD-1 sequences (2022-04-26),

Title: The Innovative Journey of Michael Hedvat

Introduction: Michael Hedvat, a talented inventor based in Encino, California, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Michael Hedvat holds several patents in the field of electronics and software development, with his most recent patent focusing on a cutting-edge virtual reality gaming system that has captured the attention of tech enthusiasts worldwide.

Career Highlights: With a background in engineering and a passion for pushing the boundaries of what is possible, Michael Hedvat has enjoyed a successful career marked by a series of innovative breakthroughs. His work has not only revolutionized the gaming industry but has also paved the way for advancements in virtual reality technology.

Collaborations: Throughout his career, Michael Hedvat has collaborated with leading tech companies and research institutions to bring his inventions to life. His ability to think outside the box and his dedication to excellence have made him a sought-after partner in the world of innovation.

Conclusion: Michael Hedvat's relentless pursuit of innovation and his commitment to pushing the limits of technology have established him as a visionary inventor in the field. His contributions continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.